Follow our progress.

Milestones in our journey to reinvent genetic testing.

Back to full list

Press Releases

Invitae Reports Second Quarter 2017 Results

Invitae Reports Second Quarter 2017 Results

August 07, 2017

Continued business momentum, double-digit sequential revenue growth and strengthened financial position

2017 volume guidance increased to 120,000-130,000 samples accessioned

Hosting conference call at 4:30 pm ET / 1:30 pm PT

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced financial and operating results for the quarter ended June 30, 2017.

Second Quarter 2017 Financial Highlights:

  • Generated revenue of $14.3 million in the second quarter of 2017, a 39% increase over the ...

Read more


Invitae Acquiring Good Start Genetics and CombiMatrix, Adding Comprehensive Reproductive Health Capabilities to Serve Every Stage of Life

Invitae Acquiring Good Start Genetics and CombiMatrix, Adding Comprehensive Reproductive Health Capabilities to Serve Every Stage of Life

August 03, 2017

Good Start Genetics Provides Best-in-Class Carrier and NGS Preimplantation Screening to Leading IVF Centers

CombiMatrix Trusted for Advanced DNA Diagnostics by Reproductive Health and Pediatric Specialists

Invitae to Host Webcast for Investors on August 1 at 8 am ET / 5 am PT

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced two acquisitions to establish a leading position in family health genetic information services. Invitae has entered into a definitive agreement to acquire privately held ...

Read more


Invitae Announces $73.5 Million Private Placement Offering to Fuel Strategic Growth Opportunities and Reports Preliminary Second Quarter Financial Results

Invitae Announces $73.5 Million Private Placement Offering to Fuel Strategic Growth Opportunities and Reports Preliminary Second Quarter Financial Results

August 03, 2017

Increasing momentum in Invitae’s business combined with offering proceeds position company to execute on near-term acquisition opportunities

Preliminary second quarter results demonstrate strong volume, revenue growth

Management raising guidance on 2017 volume to 120,000-130,000 samples

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, has entered into a definitive agreement to sell $73.5 million of Invitae stock in a private placement. The private placement is being led by existing investors with significant participation from ...

Read more


Invitae to Announce Second Quarter 2017 Financial Results and Host Conference Call on  August 7, 2017

Invitae to Announce Second Quarter 2017 Financial Results and Host Conference Call on August 7, 2017

July 24, 2017

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced that it will report its second quarter 2017 financial results on Monday, August 7, 2017 and will host a conference call that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent developments.

The dial-in numbers for the conference call are (844) 579-6824 for domestic callers and (763) 488-9145 for international callers, and the reservation number for ...

Read more


Invitae Acquires CancerGene Connect, Award-Winning Risk Assessment and Family  History Analysis Platform

Invitae Acquires CancerGene Connect, Award-Winning Risk Assessment and Family History Analysis Platform

June 12, 2017

Technology Expands Company’s Genome Management Support for Clinicians

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, has acquired Ommdom Inc., which develops healthcare software, including CancerGene Connect, one of the most efficient, end-to-end platforms available for collecting and managing genetic family histories. The acquisition expands the company’s suite of genome management offerings designed to help patients and clinicians use genetic information as part of mainstream medical care.

CancerGene Connect was developed by clinicians for clinicians ...

Read more


ASCO Data Shows Prostate Cancer Patients with Genetic Risk Factors Missed Under Current Testing Guidelines

ASCO Data Shows Prostate Cancer Patients with Genetic Risk Factors Missed Under Current Testing Guidelines

June 05, 2017

A new analysis of genetic testing results among prostate cancer patients shows a substantial portion of patients with clinically significant genetic variants will be missed under current testing guidelines. These data add to the evidence supporting the re-evaluation of germline genetic testing guidelines for prostate cancer patients. The study was presented by a team including researchers from Invitae Corporation (NYSE: NVTA) and the Tulane University School of Medicine at the American Society for Clinical Oncology (ASCO) Annual Meeting in Chicago ...

Read more


Invitae to present at the Goldman Sachs 38th Annual Global Healthcare Conference

Invitae to present at the Goldman Sachs 38th Annual Global Healthcare Conference

June 01, 2017

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced that Randy Scott, executive chairman of Invitae, will present at the Goldman Sachs 38th Annual Global Healthcare Conference on Thursday, June 15, 2017 at 8:40 a.m. Pacific at the Terranea Resort in Rancho Palos Verdes, California.

The live, listen-only webcast of the presentation may be accessed by visiting the investors section of the company’s website at ir.invitae.com. A replay of the webcast ...

Read more


Invitae Broadens Management Team to Scale Expanding Business and Meet Rising Demand

Invitae Broadens Management Team to Scale Expanding Business and Meet Rising Demand

May 25, 2017

Shelly Guyer appointed chief financial officer as Lee Bendekgey takes on role of chief operating officer

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, announced that industry veteran Shelly Guyer, most recently chief financial officer at Veracyte, Inc., a genomic diagnostics company, has been named chief financial officer, effective June 12, 2017. Upon her appointment, Invitae’s current chief financial officer, Lee Bendekgey, will fully transition to the role of chief operating officer.

 

“I’m thrilled to ...

Read more


Invitae to Present at the UBS Global Healthcare Conference

Invitae to Present at the UBS Global Healthcare Conference

May 12, 2017

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced that Sean George, chief executive officer of Invitae, will present at the UBS Global Healthcare Conference on Monday, May 22, 2017 at 11:00 a.m. Eastern / 8:00 a.m. Pacific in New York City.

The live, listen-only webcast of the presentation may be accessed by visiting the Investors section of the company’s website at ir.invitae.com. A replay of the webcast will be ...

Read more


Invitae Exceeds 26,000 Samples Accessioned, Reports Revenue of $10.3 Million and Net Loss of $0.64 Per Share in First Quarter 2017

Invitae Exceeds 26,000 Samples Accessioned, Reports Revenue of $10.3 Million and Net Loss of $0.64 Per Share in First Quarter 2017

May 08, 2017

Management expects full-year 2017 revenue between $55 million and $65 million

Hosting conference call at 4:30 pm ET / 1:30 pm PT

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced financial and operating results for the quarter ended March 31, 2017.

First Quarter 2017 Financial Highlights:

  • Generated revenue of $10.3 million in the first quarter of 2017, compared to $4.0 million in the first quarter of 2016.
  • Accessioned more than 26 ...

Read more